An experimental mRNA-based vaccine from Moderna and Merck reduced the risk that the most deadly skin cancer would spread, by 65%, compared to immunotherapy treatment alone, the companies reported on Monday.
CHICAGO (Reuters) - Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. | 08:21am